PENTAQUINE (SN-13,276), A THERAPEUTIC AGENT EFFECTIVE IN REDUCING THE RELAPSE RATE IN VIV AX MALARIA

This investigation was carried out under contract, recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and the University of Chicago. This work was further aided by the participation of Army Medical officers assigned to the project by the Surgeon General, U. S. Army.

Through a cooperative arrangement between Professor Clay G. Huff and Dr. Frederick Coulston, Department of Bacteriology and Parasitology, and the Malarial Research Unit, Department of Medicine, the former group bred Anopheles quadrimaculatus mosquitoes, supervised their infection and the inoculation of volunteers, and determined the intensity of infection in the salivary glands of the mosquitoes. The latter group assumed the responsibility for clinical care of patients studied by both groups.

The authors express their thanks to the Malaria Study Section of the National Institute of Health for editorial assistance and for arrangements in regard to the publication of this paper. They are also grateful to the Abbott Laboratories, E. I. du Pont de Nemours and Company, Inc., E. R. Squibb and Sons, Eli Lilly and Company, Sharp and Dohme, Inc., and Wyeth, Inc., for contributing toward the publication costs.

PMC Copyright notice

PMCID: PMC438886 PMID: 16695631